Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Parenteral replenishment of fluid and calories in patients unable to take adequate oral intake,Correction of fluid and electrolyte imbalances,As a vehicle for intravenous drug administration
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Dextrose has a plasma half-life of approximately 1-2 hours; sodium and chloride have half-lives that depend on renal function and hydration status, typically 6-12 hours for sodium. In clinical context, half-life is not typically used for fluid and electrolyte replacement.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the citric acid cycle; sodium chloride is not metabolized.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose and sodium chloride are endogenous substances. Dextrose is metabolized to CO2 and water; excess is excreted renally as glucose. Sodium and chloride are primarily excreted renally, with minimal biliary/fecal elimination. Nearly 100% of infused sodium and chloride are eliminated renally under normal conditions.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: negligible (<1%). Sodium: negligible. Chloride: negligible.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: approximately 0.2 L/kg (extracellular fluid). Sodium: 0.2 L/kg (extracellular fluid). Chloride: 0.2 L/kg (extracellular fluid). These reflect distribution primarily in extracellular space.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
e GFR <30 m L/min: Use with caution; monitor fluid and electrolyte balance; adjust volume and rate based on renal function and urine output.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment required; use caution in severe hepatic impairment due to potential volume overload.
No dosage adjustment required for hepatic impairment.
Weight-based: Initial dose 5-10 m L/kg, may repeat as needed; maintenance: 80-120 m L/kg/day for infants and 60-80 m L/kg/day for older children; adjust rate based on clinical response and glucose/electrolyte monitoring.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Start at lower end of adult dose; monitor for fluid overload, hyperglycemia, and electrolyte disturbances due to decreased renal function and cardiovascular reserve.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperglycemia, especially in patients with diabetes mellitus or impaired glucose tolerance,Risk of fluid overload, particularly in patients with cardiac or renal impairment,Electrolyte imbalances with prolonged use or rapid infusion,May cause phlebitis or extravasation at infusion site,Use with caution in patients with intracranial or intraspinal hemorrhage
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia (severe) or diabetic coma with hyperglycemia,Hypersensitivity to any component,Clinically significant hypernatremia or fluid overload,Patients with increased intracranial pressure
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. However, due to dextrose content, patients with diabetes should monitor blood glucose closely. Avoid concurrent use with alcohol due to risk of hypoglycemia or hyperglycemia.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of large volumes may cause electrolyte imbalances and fluid overload, potentially affecting fetal hydration status.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Both dextrose and sodium chloride are endogenous substances and are present in breast milk at concentrations similar to maternal plasma. M/P ratio: Not applicable; considered compatible with breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dose adjustments required for standard maintenance fluids. However, pregnant patients may have increased volume of distribution and renal clearance; monitor for fluid and electrolyte balance, and adjust infusion rate accordingly to prevent overload.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Contains 10% dextrose (100 g/L) and 0.2% sodium chloride (34 m Eq/L Na+ and Cl-). Osmolality approximately 505 m Osm/L, p H ~4.0. Provides 340 kcal/L. Use with caution in patients with fluid overload, heart failure, or renal impairment. Monitor serum glucose, electrolytes, and fluid balance. Not for use as a sole source of nutrition; consider thiamine supplementation in chronic alcoholics to prevent Wernicke's encephalopathy. Do not administer with blood products through same IV line.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution provides sugar (dextrose) and salt (sodium chloride) to help maintain your body's fluid and energy balance.,Report any signs of allergic reaction, such as rash, itching, or difficulty breathing, during infusion.,Inform your healthcare provider if you have diabetes, high blood pressure, heart failure, or kidney disease.,This solution is given through a vein; you may feel warmth or discomfort at the injection site.,Follow your doctor's instructions regarding fluid intake and monitoring of blood sugar levels.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.